Compare Sanofi SA (SNY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Sony Group Corp — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Sony Group Corp trades at $24.12 (market cap $136.87B). The key difference: Sony Group Corp is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Sony Group Corp for 96 Days on average.
| SNY | SONY | |
|---|---|---|
Market Cap | $95.18B | $136.87B |
Volume | 2,995,646 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $52.34 | $30.26 |
52-Week Low | $39.51 | $19.32 |
Typical Hold Time | 94 Days | 96 Days |
Enterprise Value | $114.48B | $134.77B |
Dividend Yield | 6.01% | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Sony trades at $24.12, up 2.55% today, with a bullish technical outlook supported by moving averages. The company reported mixed quarterly results with two beats and one miss, while full-year 2025 showed strong revenue of $12.96T and net income of $1.14T. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations, though 2026 projections indicate potential profitability challenges with negative net income margins.
Sony presents a compelling value opportunity with reasonable valuation metrics (P/E 20.34, P/S 1.79) and strong cash flow generation, but faces headwinds from projected 2026 profitability decline. The entertainment and technology conglomerate benefits from diverse revenue streams and intellectual property strength, though investors should monitor execution risks amid competitive pressures and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
